Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.72 |
| ▸ | MMP1 | P03956 | 10/20 | 0.72 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 4/20 | 0.44 |
| ▸ | MMP10 | P09238 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204263 | 0.90 | MMP13 (0.59) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7204557 | 0.90 | MMP13 (0.69) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7207157 | 0.89 | MMP13 (0.56) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7207973 | 0.89 | MMP13 (0.57) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7199642 | 0.89 | MMP13 (0.57) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7203056 | 0.86 | MMP13 (0.58) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7208196 | 0.85 | MMP13 (0.56) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7201798 | 0.85 | MMP13 (0.74) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7205953 | 0.85 | MMP13 (0.71) | MMP13MMP1ADAMTS4ADAM17MMP3 | |
| SCHEMBL7204537 | 0.84 | MMP1 (0.56) | MMP13MMP1ADAMTS4ADAM17MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP13 4/4885MMP1 8/4885ADAMTS4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.